Eli Lilly And Co
NYSE: LLY
Stock price
939.47 USD
(+409.23%) 5 years
Financial Performance
5Y price score: 628
against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index,
while a score above 100 means it outperformed the S&P 500.
10Y return: 1,209.9%
US$ Per
Share
Earnings per share
Free cash flow per share
Stock price
By default your notes are visible only to you.
623.7
52-week range
1133.9
Your model inputs
| Required return / cost of capital |
| FCFF terminal growth rate |
Valuation
Free Cash Flow Yield
1.1 %
Dividend Yield TTM
0.7 %
Market cap $
$ 887,629.1
Price / Earnings TTM
40.9
Price / Book TTM
31.8
PEG TTM
0.4
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
31.1 %
421.7 %
1,209.9 %
Free cash flow per share growth
2,080.2 %
113.8 %
725.1 %
Earnings per share growth
96 %
254.7 %
952.8 %
Founded: 1,876
Employees: 43,000
Business Summary:
all figures in USD Millions except per share data
Periods:
View:
Forecast:
Averages
based on historical growth rates (CAGR) and average margins for last 10 or max, available and up to 10 years.
Analysts
Average Revenue and Net Income forecast estimates from analysts who cover the stock.
Custom
you can edit default forecast based on averages or analysts consensus and use it to calculate fair value based on your assumptions.
ㅤ
Please log in / sign up view historical financials. It is free under TopFunds
Light plan.
Increase
Decrease
Total
| Required return / cost of capital |
| FCFF terminal growth rate |
| Free cash flow forecast |
| Terminal value |
| ㅤPV breakdown |
| Enterprise value / PV of FCF |
| ㅤPlus / (Less): Net Debt |
| ㅤLess: preferred stock |
| ㅤLess: minority interest |
| Market cap |
| ㅤNumber of shares |
| Price per share |
Please log in / sign up to calculate fair value based on selected inputs
Latest Earnings Call Takeaways
2025 Q4 (Feb 4, 2026)
1) Strong Financial Performance
- Full-year revenue for 2025 reached $65.2 billion, a 45% increase compared to 2024.
- Q4 revenue grew 43% YoY, driven by key products, with earnings per share rising 86% to $7.54.
- Gross margin remained stable at 83.2%, while R&D and marketing expenses increased by 26% and 29%, respectively.
- Non-GAAP performance margin improved to 47.2%, up 4.2 percentage points from Q4 2024.
2) Product and Pipeline Advancements
- Launched new medicines like Inlureo and expanded indications for Omvo and Jayperca.
- Significant clinical progress with 25 phase three trials and submissions for Orforglipron in obesity across the US and 40 countries.
- Strong performance from key products, with Mounjaro and Zepbound leading in their respective markets, achieving over 55% and 70% of new prescriptions in the US.
- Continued investment in AI for drug discovery and expansion of manufacturing capabilities, with a commitment of $55 billion since 2020.
3) Market Dynamics and Challenges
- Anticipated pricing pressures in 2026 due to government agreements and Medicaid changes, expected to impact revenue growth by low to mid-teens percentage.
- Competition in the incretin market is increasing, but Lilly expects Orforglipron to expand the overall market rather than cannibalize existing products.
- Some challenges in securing Medicaid coverage, particularly in states like California, which may reduce access temporarily.
4) Guidance and Future Outlook
- 2026 revenue guidance set between $80 billion and $83 billion, representing a 25% increase from 2025.
- Expected earnings per share between $33.50 and $35, indicating continued strong growth.
- Anticipated launch of Orforglipron in the US and most international markets by 2027, with a focus on expanding access and market penetration.
- Continued investment in R&D with 36 active Phase III programs and plans for new trials in various therapeutic areas.
5) Leadership and Strategic Focus
- Strengthened leadership team with new executives in key roles, enhancing strategic direction.
- Focus on expanding the incretin portfolio and exploring new therapeutic areas, including immunology and oncology.
- The call lacked detailed Q&A on specific product launch metrics and competitive positioning against emerging therapies.
Bottom line: Eli Lilly's strong financial performance in 2025, driven by innovative product launches and a robust pipeline, positions the company well for future growth despite anticipated pricing pressures and market competition. The strategic focus on expanding access to obesity treatments and leveraging AI in drug development further enhances its long-term outlook for shareholders.
Eli Lilly And Co — Financial Overview, Stock Price, Market Cap
Eli Lilly And Co is a company. Founded in 1876. As of April 13, 2026, the company's market capitalization is $887629105930 with a current stock price of $939.47.